Eli Lilly and Company

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Technische Universitat Darmstadt

Gerd Ruehter

Daniel Jon Sall

Jolie Anne Bastian

Theo Schotten

Felix Hausch

Steffen Gaali

Andreas Bracher

Xixi Feng

Alexander Kirschner

Jeffrey A Dodge

Brian Stephen Muehl

Kenneth Jeff Thrasher

Louis Nickolaus Jungheim

Cynthia Darshini Jesudason

Wolfgang Stenzel

Russell Dean Stucky

David Michael Remick

John Arnold Werner

Miles Goodman Siegel

Rushad Eruch Karanjawala

Britta Evers

Peter Nussbaumer

Bert Klebl

Jan Eickhoff

Carsten Schultz-Fademrecht

The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

Selective FKBP51 ligands for treatment of psychiatric disorders

The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions. 

The present invention relates to 2-imidazo[1,2-a]pyridine group containing &#x3b2;adrenergic receptor agonists or pharmaceutical salts thereof.

[object Object]

The present invention relates to pyrrolopyridine-3-yl group containing &#x3b2;adrenergic receptor agonists or pharmaceutical salts thereof.

The present invention relates to 2-imidazo[1,5-a]pyridine containing &#x3b2;adrenergic receptor agonists or pharmaceutical salts thereof.

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of Formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity 

3-Substituted oxindole &#x3b2;3 agonists

This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.

Substituted dipeptides as growth hormone secretagogues

The present invention relates to a &#x3b2;adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity.

Growing community of inventors

Hamburg, Germany

Gerd Ruehter